Safety of Ultrasound Contrast Agents in Stress Echocardiography

American Journal of Cardiology

Volumn 102, Issue 9, 2008, Pages 1269-1272

  Gabriel, Ruvin S ^a   Smyth, Yvonne M ^a   Menon, Venu ^a   Klein, Allan L ^a   Grimm, Richard A ^a   Thomas, James D ^a   Sabik, Ellen Mayer ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOBUTAMINE; ECHO CONTRAST MEDIUM; PERFLUTREN;

ADULT; AGED; ANAPHYLAXIS; ARTICLE; BACKACHE; BRADYCARDIA; CAUSE OF DEATH; CONTROLLED STUDY; DEATH; DIAPHORESIS; DISEASE ASSOCIATION; DRUG SAFETY; DYSPNEA; FEMALE; FLUSHING; HEART ARREST; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; STRESS ECHOCARDIOGRAPHY; SUPRAVENTRICULAR TACHYCARDIA; THORAX PAIN; VOMITING;

AGED; CARDIOTONIC AGENTS; CONTRAST MEDIA; DOBUTAMINE; ECHOCARDIOGRAPHY, STRESS; FEMALE; HEART ARREST; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; TACHYCARDIA, VENTRICULAR;

EID: 54549109016     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.06.066     Document Type: Article

References (19)

1. Bouakaz A., and de Jong N. WFUMB Safety Symposium on Echo-Contrast Agents: nature and types of ultrasound contrast agents. Ultrasound Med Biol 33 (2007) 187-196
2. Olszewski R., Timperley J., Szmigielski C., Monaghan M., Nihoyannopoulos P., Senior R., and Becher H. The clinical applications of contrast echocardiography. Eur J Echocardiogr 8 (2007) S13-S23
3. Dolan M.S., Riad K., El-Shafei A., Puri S., Tamirisa K., Bierig M., St. Vrain J., McKinney L., Havens E., Habermehl K., et al. Effect of intravenous contrast for left ventricular opacification and border definition on sensitivity and specificity of dobutamine stress echocardiography compared with coronary angiography in technically difficult patients. Am Heart J 142 (2001) 908-915
4. Rainbird A.J., Mulvagh S.L., Oh J.K., McCully R.B., Klarich K.W., Shub C., Mahoney D.W., and Pellikka P.A. Contrast dobutamine stress echocardiography: clinical practice assessment in 300 consecutive patients. J Am Soc Echocardiogr 14 (2001) 378-385
5. Plana J.C., Mikati I.A., Dokainish H., Lakkis N., Abukhalil J., Davis R., Hetzell B.C., and Zoghbi W.A. A randomized cross-over study for evaluation of the effect of image optimization with contrast on the diagnostic accuracy of dobutamine echocardiography in coronary artery disease. J Am Coll Cardiol Imaging 1 (2008) 145-152
6. United States Food and Drug Administration. Micro-bubble contrast agents (marketed as Definity [perflutren lipid microsphere] injectable suspension and Optison [perflutren protein-type A microspheres for injection]). Available at: http://www.fda.gov/medwatch/safety/2007/safety07.htm#bubble. Accessed January 4, 2008.
7. Douglas P.S., Weyman A.E., Lindner J.R., and Wei K. Contrast echocardiography: past, present and . . . future?. J Am Coll Cardiol Imaging 1 (2008) 107-110
8. Grayburn P.A. Product safety compromises patient safety (an unjustified black box warning on ultrasound contrast agents by the Food and Drug Administration). Am J Cardiol 101 (2008) 892-893
9. Kusnetzky L.L., Khalid A., Khumri T.M., Moe T.G., Jones P.G., and Main M.L. Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent: results in 18,671 patients. J Am Coll Cardiol 51 (2008) 1704-1706
10. Main M.L., Goldman J.H., and Grayburn P.A. Thinking outside the "box"-the ultrasound contrast controversy. J Am Coll Cardiol 50 (2007) 2434-2437
11. Bruce R.A., Kusumi F., and Hosmer D. Maximal oxygen intake and nomographic assessment of functional aerobic impairment in cardiovascular disease. Am Heart J 85 (1973) 546-562
12. Tardif J.C., Dore A., Chan K.L., Fagan S., Honos G., Marcotte F., Yu E., Siu S., Dumesnil J., Arsenault M., et al. Economic impact of contrast stress echocardiography on the diagnosis and initial treatment of patients with suspected coronary artery disease. J Am Soc Echocardiogr 15 (2002) 1335-1345
13. Thanigaraj S., Nease Jr. R.F., Schechtman K.B., Wade R.L., Loslo S., and Perez J.E. Use of contrast for image enhancement during stress echocardiography is cost-effective and reduces additional diagnostic testing. Am J Cardiol 87 (2001) 1430-1432
14. Tsutsui J.M., Elhendy A., Anderson J.R., Xie F., McGrain A.C., and Porter T.R. Prognostic value of dobutamine stress myocardial contrast perfusion echocardiography. Circulation 112 (2005) 1444-1450
15. United States Food and Drug Administration. Information for healthcare professionals: micro-bubble contrast agents (marketed as Definity [perflutren lipid microsphere] injectable suspension and Optison [perflutren protein-type A microspheres for injection]). Available at: http://www.fda.gov/cder/drug/InfoSheets/HCP/microbubbleHCP.htm. Accessed January 4, 2008.
16. Geleijnse M.L., Fioretti P.M., and Roelandt J.R. Methodology, feasibility, safety and diagnostic accuracy of dobutamine stress echocardiography. J Am Coll Cardiol 30 (1997) 595-606
17. Kane G.C., Hepinstall M.J., Kidd G.M., Kuehl C.A., Murphy A.T., Nelson J.M., Schneider L., Stussy V.L., Warmsbecker J.A., Miller Jr. F.A., et al. Safety of stress echocardiography supervised by registered nurses: results of a 2-year audit of 15,404 patients. J Am Soc Echocardiogr 21 (2008) 337-341
18. Varga A., Garcia M.A., and Picano E. Safety of stress echocardiography (from the International Stress Echo Complication Registry). Am J Cardiol 98 (2006) 541-543
19. Stuart Jr. R.J., and Ellestad M.H. National survey of exercise stress testing facilities. Chest 77 (1980) 94-97